Rainbow Warrior heading to sub-Antarctic Islands

Posted on by

The Rainbow Warrior is heading to the Auckland Islands which is home to critically endangered sea lions, yellow eyed penguins and Gibsons albatross. The islands and surrounding marine reserve are listed as a World Heritage Area, alongside the Egyptian Pyramids and the Grand Canyon.

Following the departure from Lyttleton yesterday, the Rainbow Warrior is currently sailing through the oil drilling zone off Canterbury that Anadarko plans to drill in by the end of 2013. Here the Rainbow Warrior crew saw juvenile sperm whales feeding on the surface surrounded by royal albatross, giant petrels and a number of other sea birds who call this area home.

"The Government wants to open up vast areas for deep sea oil drilling south of Dunedin, Stewart Island, and into the wild seas towards the Auckland Islands. Many of our incredible and rare native birds, sea lions and whales live here and would be at risk," said Bunny McDiarmid, Executive Director of Greenpeace New Zealand.

The Rainbow Warrior is expected to arrive at the Auckland Islands on Thursday 31 January and depart Sunday 3 February after documenting some of our most marvellous wildlife. On Monday 4 February they will be documenting the wildlife of Snares Island, south of Stewart Island.

In December the Government also gave out new deep sea oil and gas exploration permits:

- Out from Dunedin to Shell, OMV and Mitsui in the Great South Basin

- Out from Wellington/Wairarapa/Marlborough to Anadarko which also puts Kaikoura in the the spill zone

Read more:

Rainbow Warrior heading to sub-Antarctic Islands

Health care law means free clinics have to accept payments

Posted on by

Free health clinics around the Kansas City area, like many across the country, are shedding their free designation and preparing to accept payment from most patients as they adapt to the federal health care law.

The shift will be a big one, especially for the bustling Kansas City Free Health Clinic in midtown. Its one of the largest free clinics in the country, treating upward of 15,000 patients a year with more than 100 staff members and 1,000 volunteers.

In its 42 years, KC Free, as its commonly called, hasnt charged fees or billed patients for care. And it has seen only the uninsured.

Soon, all that will change.

Like several other free clinics across the country, KC Free will soon accept Medicaid and add a sliding fee scale. The dramatic shift in the non-profits business model is necessary under the new law, its leaders say, and will allow the clinic to continue caring for many of Kansas Citys most vulnerable residents.

The face of health care is changing, and we are changing with it. We must, Sheri Wood, the clinics executive director, wrote in a letter to volunteers and supporters in December.

Similarly, the Health Partnership Clinic of Johnson County has shifted its structure; and the Duquesne Clinic in Kansas City, Kan., has changed the definition of whom it serves and may start accepting Medicaid. Other health care providers are moving away from an urgent care approach in an effort to become a primary medical home for patients. Community mental health centers have started offering medical services to some patients, too.

With federal law aiming to expand health coverage, the entire safety net is realigning in preparation for an influx of patients accessing care for the ry first time, or for the first time in a very long time. And yet, parts of the law itself are still unclear, and much of how everything unfolds locally depends on how Missouri and Kansas implement the law.

We are entering a new era, and I think that free clinics are very consciously trying to decide what the best path is, said Julie Darnell, professor of Health Policy at the University of Illinois-Chicago.

A clinic for hippies

See the article here:

Health care law means free clinics have to accept payments

Jones: Health care, child safety are legislative focus

Posted on by

Sen. Shannon Jones said she is impressed with recent development in the city during a meet and greet Monday at Cincinnati State Middletown.

The Clearcreek Twp. Republican, who represents Ohios 7th Senate District, will now represent constituents in the citys 4th Ward and parts of the 2nd Ward because of redistricting.

Middletown really has a lot going on, she said, citing the East End development and the rejuvenation of this downtown area.

Jones is entering her seventh year working in Columbus, first taking office in the Ohio House in January 2007.

She was appointed to her Senate seat in August 2009 following the death of the late Sen. Bob Schuler, and subsequently elected in November 2010. The district had included Warren Countys portion of Middletown. She talked exclusively with The Middletown Journal during her visit Monday.

Q: Middletowns 4th and 2nd wards are rather different from the suburban communities youve represented in the past. How can you help these two areas of the city?

A: I think the biggest thing I can do it to just be present and to listen to people, rather than me dictate to them what their needs are. Im here today to listen to whats on peoples minds.

Q: What do you hope to learn about the community?

A: I hope to learn what the core institutions are in the community because that gives me a sense of what the community values are, as well as the key people who are active in the community. Once you sort of know what the landscape looks like, I just plan to be around and listen and learn.

Q: It appears Middletown and the region are becoming an educational hub in addition to being a health care hub. Is this good for the region?

View post:

Jones: Health care, child safety are legislative focus

Health Care Earnings Invigorate the Dow

Posted on by

It's a good day for companies reporting earnings, and strong quarters are powering the Dow Jones Industrial Average (DJINDICES: ^DJI) higher. The Dow has rocketed to yet another 52-week high, continuing to surge through the start of 2013. As of 2:20 p.m. EST, the index has pulled in gains of 70 points, or 0.51%. Let's check out the biggest names making moves today.

A healthy dose of optimism It's a great day to be a health care investor, and Pfizer (NYSE: PFE) is leading the charge on the Dow. Along with several other companies, Pfizer reported earnings that smashed expectations. The company's profit almost quadrupled from a year ago, buoyed by its sale of its nutrition business to Nestle. Despite the patent loss of best-selling blockbuster Lipitor last year, Pfizer's earnings, even without the Nestle sale, slightly topped analyst projections. And despite the hit to Lipitor sales, revenue also beat the Street's best guess.

So far, Pfizer's shares have risen more than 3.2% to hit a new 52-week high.

The optimism around the medical industry has pushed Merck (NYSE: MRK) higher as well, even though the company doesn't report its quarterly data until later in the week. Merck is among the leaders of the Dow, up 1.5% so far today. The company is dealing with its own patent-loss blues, as declining sales of Singulair have weighed on growth expectations. Merck investors could use a good report; the stock has lost nearly 6% over the past three months.

Johnson & Johnson (NYSE: JNJ) and Unitedhealth Group have also swung up on the day, with shares gaining a little more than 1% each. J&J recently reported earnings that beat expectations, but its 2013 guidance disappointed Wall Street. The company is debating selling or spinning off its diagnostics business in its search for new growth. The guidance hit hasn't stopped this stock from hitting a new 52-week high as well, however.

Even outside the health care field, stocks on the Dow lean heavily toward winners. However, Hewlett-Packard (NYSE: HPQ) is leading the small corps of laggards down today, with shares falling 3.9%. Reports have surfaced from a PDF file on the company's website that HP may be preparing to launch its own version of Google's Chromebook, a laptop operating on Google's Chrome OS. However, with the PC market under fire, it'll take a lot more than that to turn this beleaguered company around.

Interested in Johnson & Johnson? Health care stocks are dominating the headlines today, and there's no bigger player in the sector than medical colossus Johnson & Johnson. Offering everything from baby powder to biologics, the company is considered by some to be spread too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand-new premium report on Johnson & Johnson. To claim your copy, simply click here now for instant access.

The rest is here:

Health Care Earnings Invigorate the Dow

Cardium Announces Presentaton at The 2013 Cell & Gene Therapy Forum

Posted on by

SAN DIEGO, Jan. 29, 2013 /PRNewswire/ --Cardium Therapeutics (NYSE MKT: CXM) today announced a presentation at the 2013 Phacilitate Annual Cell & Gene Therapy Forum in Washington, DC. The Company's presentation, "Optimizing Phase III Trial Design for Generx (Ad5FGF-4)" by Cardium's Chief Scientific Officer, Gabor M. Rubanyi, M.D., Ph.D. outlined the current scientific knowledge about the mechanistic basis of adaptive coronary collateral growth, the biological processes to be targeted by therapeutic angiogenesis, and discussed the lessons learned during the past decade of the Company's Generx clinical development program. The presentation is available for viewing at http://www.cardiumthx.com/generx.html.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

"The presentation yesterday reviewed new techniques that have been implemented to optimize our international Phase 3 ASPIRE clinical study for the Company's Generx (Ad5FGF-4) DNA-based angiogenic growth factor drug candidate, including: (1) diagnostic identification of patients likely to be more responsive to angiogenic therapy; (2) new balloon catheter-based delivery methods designed to boost adenovector gene delivery and enhance angiogenic growth factor efficiency; and (3) selection of relevant clinical endpoints which may be useful in future clinical studies and help advance the field of therapeutic angiogenesis," stated Christopher J. Reinhard, Cardium's Chairman and CEO.

Generx is an interventional cardiology-focused product candidate that is being developed to offer a one-time, non-surgical option for the treatment of a medical condition termed cardiac microvascular insufficiency (CMI) in patients with myocardial ischemia and symptomatic chronic stable angina pectoris due to coronary artery disease. Patients with CMI have had an insufficient angiogenic response to their current disease state and may benefit from a biological therapy that enhances cardiac perfusion through the facilitation of collateral vessel formation. Currently, patient inclusion in the ASPIRE study requires evidence of stress induced reversible myocardial ischemia as measured by SPECT imaging. The goal of the Company's Generx product candidate is to improve blood flow to the heart muscle by promoting and enhancing cardiac perfusion through the enlargement of pre-existing collateral arterioles (arteriogenesis) and the formation of new capillary vessels (angiogenesis). Various catheter-based imaging diagnostics including fractional flow reserve and washout collaterometry could enhance the clinical adoption of this non-surgical therapeutic angiogenesis approach following initial registration.

Cardium's extensive preclinical and clinical studies have been instrumental in identifying cardiac ischemia as a key facilitator of non-surgical DNA-based angiogenic therapy. Improved adenovector administration methods combine non-surgical, percutaneous balloon catheter-based delivery to transiently induce ischemia together with the use of nitroglycerin to enhance vector uptake. By increasing cell transfection efficiency and reaching both the peri-ischemic regions and pre-existing collaterals in the heart, this modified approach offers the potential to effectively simulate both angiogenesis and arteriogenesis to bring about improved blood flow. Cardium's new delivery techniques are also designed to provide uniform Generx uptake, to reduce response variability and to allow for the potential treatment of patients with a broader range of associated coronary artery disease.

Cardium has modified the primary endpoint of the ASPIRE clinical study from the traditional measure of improvement in treadmill exercise time (ETT) to a more objective efficacy endpoint of reduction in reversible perfusion deficit based on SPECT myocardial perfusion imaging. Similar to mechanical/surgical cardiac revascularization approaches, the goal of Generx treatment is to improve myocardial perfusion (blood flow). SPECT myocardial perfusion imaging can be used to quantitatively evaluate Generx's effectiveness by measuring improved myocardial blood flow under stress, a key prognostic indicator that is associated with the regenerative process of new collateral vessel formation in and around the regions of ischemia. While walking time during ETT has been a traditional efficacy measure of anti-anginal drugs, it is based on a subjective assessment of chest pain (angina pectoris), does not directly measure improvements in cardiac blood flow, and can be affected by other variables. Positive results from the prior Phase 2a clinical study (Grines et al., J Am Coll Cardiol 2003; 42:1339-47) showed that Generx improved myocardial blood flow in the ischemic region of the hearts of patients following a single intracoronary infusion as measured by the objective efficacy endpoint of SPECT imaging. The observed treatment effect for patients receiving Generx was similar in magnitude to that reported in the literature for patients undergoing angioplasty/stent or revascularization procedures with reversible perfusion defects of comparable size at one year following these procedures.

ASPIRE Study

The ASPIRE study is a 100-patient, randomized and controlled multi-center study currently enrolling patients at up to eight leading cardiology centers in the Russian Federation. The ASPIRE study is designed to further evaluate the safety and effectiveness of Cardium's Generx DNA-based angiogenic product candidate, which has already been tested in clinical studies involving 650 patients at more than one hundred medical centers in the U.S., Europe and elsewhere. The efficacy of Generx is being quantitatively assessed using rest and stress SPECT (Single-Photon Emission Computed Tomography) myocardial imaging to measure improvements in microvascular cardiac perfusion following a one-time, non-surgical, catheter-based administration of Generx. The Cedars-Sinai Medical Center Nuclear Cardiology Core Laboratory in Los Angeles, California, is the central core lab for the study and is responsible for the analysis of SPECT myocardial imaging data electronically transmitted from the Russian medical centers participating in the ASPIRE study. The Russian Health Authority has assigned Generx the therapeutic drug trade name of Cardionovo for marketing and sales in Russia.

An independent long-term prospective study published in Circulation (Meier et al, Circ. 2007; 116:975-983) provided key evidence indicating that men and women with more recruitable collateral circulation have a better chance of surviving a heart attack than patients who have less developed collateral circulation. This important study quantitatively evaluated coronary collateral blood flow in 845 patients with coronary artery disease during a 10-year follow-up period and showed that long-term cardiac mortality was approximately 66% lower in patients with a well-developed coronary collateral network (p=0.019). For the first time, this study showed the importance of collateral circulation beyond simply the relief of angina and provided further support of the potential for long term benefits from angiogenic therapy.

About Cardium

Visit link:

Cardium Announces Presentaton at The 2013 Cell & Gene Therapy Forum

Freedom of speech must not extend to right to offend: Tewari

Posted on by

New Delhi, Jan 29 (IANS) "Democratisation" of the information sector, with easy access to news and social media platforms, should take into account implications on social ethics and norms, and freedom of speech should not extend to the right to offend, Information and Broadcasting Minister Manish Tewari said here Tuesday.

Addressing a function of the Broadcast Engineering Society, Tewari said media should take to self-regulation "as an instinct".

"With the democratization of the information paradigm, it has to take into account what are the implications on social ethics, social milieu, social norms... Freedom of speech should not extend to the right to offend", he continued, adding that a "remedy" should be found to the issue.

Referring to social media, Tewari said there is "need to make a distinction between right to privacy and the right to know".

"The right to anonymity can be corrosive to social order," he said.

The minister's comments can be seen in reference to many postings critical of the government by anonymous accounts as well as imposter accounts posing as the Prime Minister's Office or poking fun at the prime minister on the social media network Twitter.

The minister said the broadcasting space has seen a huge expansion in the past two decades, from one broadcaster in 1990 to over 850 television channels, while FM radio has also expanded in the past five years. The social media has also expanded with around seven crore users.

This posed a question "whether regulation has been able to keep pace with the march of technology," said Tewari.

"For orderly development of any sector, it is a prerequisite that enabling regulations of statutory architecture should keep pace with the changes as it unfolds," he added.

On TRPs and sensationalism in TV media, Tewari said the issue needs to be deliberated whether it is due to the "skewed revenue model or an addiction that people have got into".

See the rest here:

Freedom of speech must not extend to right to offend: Tewari

Freedom Valu Selects PeopleMatter to do More Than Just Job Apps

Posted on by

PeopleMatter Automates HR with Comprehensive Hire-to-Retire Solution

Charleston, SC (PRWEB) January 29, 2013

We were looking for a software package that could do more than applicant tracking, said Rick Cagle, Vice President and Director of Operations for Erickson Oil Products/Freedom Valu Centers. We wanted a system that offered training and scheduling, in addition to applicant tracking.

PeopleMatter provides Freedom Valu with a configurable, flexible and easy-to-use HR Platform that offers hiring, training and scheduling all from one online portal. Unlike many HR solutions in the market, PeopleMatter is designed specifically for the service industry and hourly workforce. All the Platforms tools and features are built to accommodate the unique needs of multi-unit operators a key request for companies like Freedom Valu.

With stores located in the metropolitan and suburban areas of Minnesota, Wisconsin, South Dakota and Michigan, Freedom Valu managers can easily share applications and employee schedules across locations. Additionally, if an employee moves from one state to another, managers can quickly transfer the employees file to the Freedom location closest to the employees new address. The software syncs all of the data and employees instantly throughout the system and keeps on-the-go teams up-to-date.

We have been very impressed with the speed and accuracy of moving our information into the system. The transition has been good from the beginning to deployment, said Rick Cagle, Vice President and Director of Operations Erickson Oil Products/Freedom Valu Centers. Traditionally implementations are laborious. But turning on PeopleMatter and using the system has been easy and flawless.

Using the integrated modules and components of the PeopleMatter Platform provides a lot of flexibility not found in point solutions. Capabilities include the:

By providing an integrated training and scheduling solution, PeopleMatter meets a need Freedom Valus previous point solution left unfulfilled. PeopleMatters comprehensive Platform works how today's workforce works via mobile smartphones, tablets, browsers and voice-activated devices.

Having clients move from a point solution to the PeopleMatter Platform is always a validation of our product, said Nate DaPore, PeopleMatter President and Chief Executive Officer. It is wonderful to see new clients like Freedom Valu Centers embrace our easy to-use tools that meets their needs and grows with the company.

About Freedom Valu Centers

Read the rest here:

Freedom Valu Selects PeopleMatter to do More Than Just Job Apps

Watchdog launches global press freedom 'indicator'

Posted on by

Reporters Without Borders on Wednesday launched a new indicator measuring global press freedom by aggregating the scores of its annual index, from perennial table-topping Finland to worst offenders Eritrea.

"In view of the emergence of new technologies and the interdependence of governments and peoples, the freedom to produce and circulate news and information needs to be evaluated at the planetary as well as national level," the Paris-based watchdog said.

It said that its new indicator, launched after one of the deadliest years ever for journalists worldwide, stood at 3395, which would become a reference point.

Northern European countries topped the rankings of its separate Press Freedom Index, while the small, reclusive African nation of Eritrea came last.

The fluctuations caused by the Arab Spring in the rankings had now stabilised, the report said.

"The ranking of most countries is no longer attributable to dramatic political developments. This year's index is a better reflection of the attitudes and intentions of governments towards media freedom in the medium or long term," it said.

The biggest gain was achieved by Malawi, which moved up 71 spots to 75th and the biggest fall was recorded by war-torn Mali, which tumbled 74 places from its impressive previous ranking of 25th.

Selected rankings from Reporters Without Borders' 2013 World Press Freedom Index:

1. Finland

2. Netherlands

Go here to read the rest:

Watchdog launches global press freedom 'indicator'

Freedom Autosport starts SCC season with 6th at Daytona

Posted on by

DAYTONA BEACH, Fla.Freedom Autosport got the 2013 GRAND-AM Continental Tire Sports Car Challenge season off to a good start by finishing 6th in Fridays 2.5-hour opener. Andrew Carbonell and Rhett ODoski were the co-drivers responsible for the solid finish in the No. 26 Mazda MX-5.

Tom Long and Derek Whitis finished 13th in the No. 25 MX-5, meaning both cars left Daytona with valuable points in the Street Tuner standings.

#26 Freedom Autosport Mazda MX-5: Andrew Carbonell, Rhett O'Doski

Photo by: Eric Gilbert

This year, Freedom Autosport is honoring Marine Cpl. Christopher Singer, who made the ultimate sacrifice on January 21, 2012, during combat in Afghanistan.

Freedom Autosport has always supported the Injured Marine Semper Fi Fund, but we are also honored to remember those who have died in the line of duty, says Whitis. Fans will be able to see Cpl. Singers picture on our car all year long.

Both of the Freedom Autosport MX-5s pitted during a caution, which allowed Carbonell to get behind the wheel of the No. 26 while Long took over in the No. 25.

The pit stops were both so flawless that the cars gained positions, edging out other competitors who also took advantage of the caution.

Carbonell and Long ran nose-to-tail for a while so they could carry more speed on Daytonas banking. Carbonell had to stop under green for fuel as the race neared its end, but the teams strategy worked well, and Carbonell crossed the line in 6th.

Meanwhile, Long had to pit under green with a bent fender. The team used the stop to refuel the No. 25, so they avoided making any extra stops during the race. Long and Whitis eventually finished 13th.

Originally posted here:

Freedom Autosport starts SCC season with 6th at Daytona

Rand Paul Backs Zionist, Globalist Hype Iran Nuke Threat, Eugenics War Waged on Africans.flv – Video

Posted on by


Rand Paul Backs Zionist, Globalist Hype Iran Nuke Threat, Eugenics War Waged on Africans.flv
Isaiah 13:13-20 "Therefore I will shake the heavens, and the earth shall remove out of her place, in the wrath of the LORD of hosts, and in the day of his fierce anger. 14And it shall be as the chased roe, and as a sheep that no man taketh up: they shall every man turn to his own people, and flee every one into his own land. 15Every one that is found shall be thrust through; and every one that is joined unto them shall fall by the sword. 16Their children also shall be dashed to pieces before their eyes; their houses shall be spoiled, and their wives ravished. 17Behold, I will stir up the Medes against them, which shall not regard silver; and as for gold, they shall not delight in it. 18Their bows also shall dash the young men to pieces; and they shall have no pity on the fruit of the womb; their eye shall not spare children. 19And Babylon, the glory of kingdoms, the beauty of the Chaldees #39; excellency, shall be as when God overthrew Sodom and Gomorrah. 20It shall never be inhabited, neither shall it be dwelt in from generation to generation: neither shall the Arabian pitch tent there; neither shall the shepherds make their fold there."

By: GOCCHURCHFLORIDA

Read more here:

Rand Paul Backs Zionist, Globalist Hype Iran Nuke Threat, Eugenics War Waged on Africans.flv - Video

[92] Israel’s Eugenics Exposed, Police State Prep, GMO Virus, Latin America Flips Capitalism – Video

Posted on by


[92] Israel #39;s Eugenics Exposed, Police State Prep, GMO Virus, Latin America Flips Capitalism
Abby Martin Breaks the Set on Police State Preparations, Forced Sterilization in Israel, Killer GMOs and Latin America #39;s Economic Growth LIKE Breaking the Set @ fb.me FOLLOW Abby Martin @ twitter.com EPISODE BREAKDOWN: On this episode of Breaking the Set, Abby Martin talks about recent military exercises in Miami and Houston that have left residents terrified, what could these exercises be preparing for? Abby then talks to Alexis Baden-Mayer, Political Director for the Organic Consumers Association, about a recent discovery by the European Food Safety Authority, which found a viral gene unsafe for human consumption in almost all GMOs. Abby then talks to producer, Manuel Rapalo, about the recent EU-CELAC summit in Santiago Chile, and a trend of economic growth that is changing the Latin American region into a global economic and political powerhouse. BTS wraps up the show with a look at the history of eugenics in the US, and Israel #39;s current practice of administering forced birth control on its Ethiopian population.

By: breakingtheset

Link:

[92] Israel's Eugenics Exposed, Police State Prep, GMO Virus, Latin America Flips Capitalism - Video

Metal Gear Rising: Revengeance – ‘Cyborg Troops Trailer’ TRUE-HD QUALITY – Video

Posted on by


Metal Gear Rising: Revengeance - #39;Cyborg Troops Trailer #39; TRUE-HD QUALITY
#9658; #9658; Remember to select 720p HD #9668; #9668; Armed with swords, grenades, rocket launchers and more, you better bring your #39;S-rank #39; game if you hope to stand a chance against these cybernetic foes. Combo, parry, and zandatsu your way to victory in Metal Gear Rising: Revengeance. Subscribe to the MGR: Revengeance show for the latest videos: http://www.youtube.com Publisher: Konami Developer: PlatinumGames Genre: Action Release Date: US: February 21, 2013 EU: February 22, 2013

By: RajmanGamingHD

See the original post:

Metal Gear Rising: Revengeance - 'Cyborg Troops Trailer' TRUE-HD QUALITY - Video

Metal Gear Rising: Revengeance – Cyborg Troops Gameplay Trailer – Video

Posted on by


Metal Gear Rising: Revengeance - Cyborg Troops Gameplay Trailer
Raiden is set to face an onslaught of enemies in Platinum Games #39; take on the Metal Gear universe. Subscribe to 1UP #39;s channel for more reviews, previews, and all things gaming: http://www.youtube.com TAGS: mgs,metal gear,metal gear rising,revengeance,raiden,slasher,hf blade,cyborg,trailer,playstation 3,metal gear rising revenge,games,xbox 360,pc,Konami,Kojima Productions,MGS,Solid Snake,Naked Snake,Big Boss,Rising,ign,ignentertainment,games,gaming,video games,gameplay,hd,official,2012,"video,game",1UP,"The,1UP,Network","1UP.com"

By: The1UPNetwork

Read this article:

Metal Gear Rising: Revengeance - Cyborg Troops Gameplay Trailer - Video

Metal Gear Rising Revengeance Cyborg Troops Trailer HD – Video

Posted on by


Metal Gear Rising Revengeance Cyborg Troops Trailer HD
Metal Gear Rising Revengeance Cyborg Troops Trailer HD The first two trailers showcase the game #39;s enemy Cyborgs and Raiden #39;s #39;high-frequency blades #39; respectively Watch the first one here: http://www.youtube.com Metal Gear Rising: Revengeance will release February 22 on PlayStation 3 and Xbox 360.

By: RetroBrosTV

The rest is here:

Metal Gear Rising Revengeance Cyborg Troops Trailer HD - Video

Metal Gear Rising: Revengeance – Cyborg Troops Trailer – PS3 / Xbox 360 – Video

Posted on by


Metal Gear Rising: Revengeance - Cyborg Troops Trailer - PS3 / Xbox 360
Armed with swords, grenades, rocket launchers and more, you better bring your #39;S-rank #39; game if you hope to stand a chance against these cybernetic foes. Combo, parry, and zandatsu your way to victory in METAL GEAR RISING: REVENGEANCE.

By: ItsElvio

See the original post:

Metal Gear Rising: Revengeance - Cyborg Troops Trailer - PS3 / Xbox 360 - Video

STEAL THEIR CYBORG GATORADE! (Dope or Nope) – Video

Posted on by


STEAL THEIR CYBORG GATORADE! (Dope or Nope)
NOTE: These are just shallow first opinions. NOT A REVIEW! Subscribe to Smosh Games! bit.ly Here #39;s our first impression of the Metal Gear Solid: Revengence Demo! Get the skinny on the newest games, hot off the presses. We #39;ll bring you along on our very first play-through of the game and give you our first impressions on what works (Dope!) and what sucks (Nope). Play with us! Subscribe: bit.ly Like us on Facebook: facebook.com Follow us on Twitter: twitter.com Follow our team on twitter @smoshian @smoshanthony @atomicmari @thejovenshire @sohinki @lasercorn

By: SmoshGames

More here:

STEAL THEIR CYBORG GATORADE! (Dope or Nope) - Video